Item 1(a). | Name of Issuer: |
Prime Medicine, Inc. (the “Issuer”)
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
21 Erie Street
Cambridge, MA 02139
Item 2(a). | Names of Persons Filing: |
The names of the persons filing this report (collectively, the “Reporting Persons”) are:
Newpath Partners, L.P. (“Newpath LP”);
Newpath GP, L.P. (“Newpath GP LP”);
Newpath GP, LLC (“Newpath GP LLC”); and
Thomas Cahill (“Mr. Cahill”)
Item 2(b). | Address of Principal Business Office or, if None, Residence: |
The address of the principal business office of each of the Reporting Persons is:
800 Boylston Street, Suite 2222
Boston, MA 02199
Newpath LP is a Delaware limited partnership;
Newpath GP LP is a Delaware limited partnership;
Newpath GP LLC is a Delaware limited liability company; and
Mr. Cahill is a United States citizen
Item 2(d). | Title of Class of Securities: |
Common Stock, par value $0.00001 per share (“Common Stock”)
74168J101
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership